Susquehanna International Group
TOVX icon

Susquehanna International Group’s Theriva Biologics TOVX Stock Holding History

Susquehanna International Group’s Portfolio TOVX Stock Details TOVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.02K Buy
+24,064
New +$7.13K ﹤0.01% 13177
2024
Q1 		– Sell
-428
Closed -$4.61K – 13334
2023
Q4 		$4.61K Buy
+428
New +$5.27K ﹤0.01% 12131
2023
Q2 		– Sell
-427
Closed -$7.46K – 13146
2023
Q1 		$7.46K Buy
+427
New +$8.86K ﹤0.01% 12252
2022
Q4 		– Sell
-656
Closed -$16K – 13681
2022
Q3 		$16K Buy
656
+499
+318% +$19.2K ﹤0.01% 12680
2022
Q2 		$8K Buy
157
+82
+109% +$4.69K ﹤0.01% 12553
2022
Q1 		$5K Buy
+75
New +$5.11K ﹤0.01% 12818
2021
Q4 		– Sell
-88
Closed -$10K – 13914
2021
Q3 		$10K Buy
+88
New +$10.9K ﹤0.01% 12605
2021
Q1 		– Sell
-63
Closed -$6K – 12861
2020
Q4 		$6K Buy
+63
New +$5.52K ﹤0.01% 10929
2020
Q2 		– Sell
-984
Closed -$79K – 10935
2020
Q1 		$79K Buy
+984
New +$112K ﹤0.01% 9459
2019
Q4 		– Sell
-100
Closed -$11K – 10649
2019
Q3 		$11K Buy
100
+60
+150% +$7.25K ﹤0.01% 10012
2019
Q2 		$6K Sell
40
-9
-18% -$1.29K ﹤0.01% 10100
2019
Q1 		$8K Buy
+49
New +$8.12K ﹤0.01% 8664
2018
Q2 		– Sell
-4
Closed -$11K – 10431
2018
Q1 		$11K Buy
+4
New +$15.2K ﹤0.01% 9178
2017
Q3 		– Sell
-22
Closed -$107K – 9630
2017
Q2 		$107K Buy
22
+10
+83% +$49.8K ﹤0.01% 8659
2017
Q1 		$68K Sell
12
-7
-37% -$48.8K ﹤0.01% 8517
2016
Q4 		$128K Buy
+19
New +$195K ﹤0.01% 8956
2016
Q2 		– Sell
-48
Closed -$987K – 9332
2016
Q1 		$987K Buy
48
+21
+78% +$316K ﹤0.01% 5112
2015
Q4 		$536K Buy
+27
New +$571K ﹤0.01% 6632
2015
Q2 		– Sell
-12
Closed -$238K – 10466
2015
Q1 		$238K Buy
+12
New +$214K ﹤0.01% 8374
2014
Q2 		– Sell
-16
Closed -$360K – 10119
2014
Q1 		$360K Buy
+16
New +$331K ﹤0.01% 7306

Other funds holding TOVX

Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
VF
Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

Susquehanna International Group's TOVX Position: Q2 2026 in Review

Susquehanna International Group opened a new position in Theriva Biologics (TOVX) in Q2 2026: 24,064 shares worth $6.02K. The stake represents ﹤0.01% of the portfolio and ranks #13177 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in TOVX as recently as Q4 2023.

Susquehanna International Group first reported a position in TOVX in Q1 2014 and has held it in 20 quarters since. The position peaked at $987K in Q1 2016. 26 funds tracked by Wall St. Rank hold TOVX as of Q2 2026.

  • Susquehanna International Group held 24,064 shares of Theriva Biologics worth $6.02K as of Q2 2026.
  • Theriva Biologics was a new Susquehanna International Group position in Q2 2026.
  • Theriva Biologics made up ﹤0.01% of Susquehanna International Group's portfolio in Q2 2026, its #13177 holding.
  • Susquehanna International Group first reported a position in Theriva Biologics in Q1 2014 and has held it in 20 quarters since.
  • Susquehanna International Group's Theriva Biologics position peaked at $987K in Q1 2016.
  • 26 funds tracked by Wall St. Rank held Theriva Biologics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.